Clinical Trials Directory

Trials / Completed

CompletedNCT00141622

Sodium-Endothelial Function-CKD Study

Does Sodium Affect Endothelial Function in Individuals With Chronic Kidney Disease?

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
St George's, University of London · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Heart disease and stroke, known as cardiovascular disease, are major causes of death in people with chronic kidney disease. Abnormalities of a metabolic pathway called the "L-arginine-nitric oxide" pathway are thought to be particularly important in these people, and previous research in animals has suggested that sodium (salt) affects part of this metabolic pathway. The purpose of our research is to study the effects of sodium intake on the "L-arginine-nitric oxide" pathway, and on blood vessel function, in patients with kidney disease.

Detailed description

Chronic kidney disease (CKD) is associated with abnormalities of endothelial function (EF) and nitric oxide (NO) synthesis, and it is proposed that the endogenous NO synthase inhibitor asymmetrical dimethylarginine (ADMA) plays a central role. In man ADMA is largely metabolized by dimethylarginine dimethylaminohydrolase (DDAH), with some renal excretion occurring. Sodium inhibits DDAH expression in experimental animals and, given that CKD is frequently characterized by sodium retention, it would be interesting to study the effects of sodium loading on DDAH activity/expression, ADMA levels and EF in CKD patients. To answer these questions, we have designed a double-blind cross-over study employing Slow Sodium (150 mmol/day) and placebo for seven days in individuals with mild-to-moderate CKD. Changes in the ratio of urinary ADMA to dimethylamine (DMA, an ADMA metabolite) will be used as an marker of DDAH activity/expression. ADMA will be measured by ELISA, DMA by high performance liquid chromatography, and EF by venous occlusion plethysmography. We propose to test the following hypothesis; that in subjects with mild-to-moderate CKD under conditions of high sodium intake, as compared to low-normal sodium intake: (i) The ratio \[ADMA\]urine:\[DMA\]urine is increased (ii) \[ADMA\]plasma is increased (iii) Endothelium-dependent vasodilatation is reduced

Conditions

Interventions

TypeNameDescription
DRUGSlow sodium

Timeline

Start date
2005-04-01
Completion
2006-10-01
First posted
2005-09-01
Last updated
2007-05-15

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00141622. Inclusion in this directory is not an endorsement.